Grant: Project Grant - Priority Announcement: Cancer Research
University of Toronto
$100,000.00
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
EF 2023-24
Résumé
In Canada, survival rates for advanced high-grade serous ovarian cancer (HGSOC), the most common type of OC, remain low. The approval of several PARP inhibitors (PARPi) over the last decade has changed the way that HGSOC is managed, resulting in unprecedented survival rates. However, most patients (up to 70 %) develop resistance to PARPi, leading to disease relapse. Strategies that can prolong the benefits of PARPi are urgently needed. A promising strategy to achieve this, is to combine PARPi with an agent that targets a different cancer-related pathway, such as ATR inhibitors (ATRi).
In clinical trials, despite showing promise, PARPi+ATRi were found to result in blood toxicity. To prevent this, the Allen lab is leveraging nanoparticles (i.e., liposomes) to encapsulate PARPi and ATRi. Through this process, the Allen lab has shown a reduction in the level of blood toxicity seen with this drug combination. The proposed research will further assess these liposomes in mice that have tumors transplanted from an OC patient.
The Allen lab has also shown that PARPi+ATRi is effective at killing several different OC cells. However, some OC cells do not respond to PARPi+ATRi. As a result, the research team will use artificial intelligence (AI) and gene testing of cancer cells to develop a model that can predict which patients will respond best to PARPi+ATRi.
The research team is well-equipped to move this research forward. Dr. Allen has over 20 years of expertise in nanomedicine and drug delivery. Dr. Lheureux, a medical oncologist and clinical investigator, has significant expertise in preclinical and clinical evaluation of cancer therapies. Jazz Pharmaceuticals (our partner organization), has successfully developed a nanomedicine-based cancer treatment, further enhancing the project's potential. If successful, this project will yield sufficient data to move this nanomedicine approach into the clinic and may ultimately improve outcomes for predefined HGSOC patients.
Programme
Project Grant - Priority Announcement: Cancer Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
494635
Name
Allen Christine J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Cancer Research
Keyworddelim
Atr Inhibitor; Drug Combination; Drug Delivery; Lipid Nanoparticle; Liposome; Nanomedicine; Nanotechnology; Ovarian Cancer; Parp Inhibitor
Abstract
In Canada, survival rates for advanced high-grade serous ovarian cancer (HGSOC), the most common type of OC, remain low. The approval of several PARP inhibitors (PARPi) over the last decade has changed the way that HGSOC is managed, resulting in unprecedented survival rates. However, most patients (up to 70 %) develop resistance to PARPi, leading to disease relapse. Strategies that can prolong the benefits of PARPi are urgently needed. A promising strategy to achieve this, is to combine PARPi with an agent that targets a different cancer-related pathway, such as ATR inhibitors (ATRi).
In clinical trials, despite showing promise, PARPi+ATRi were found to result in blood toxicity. To prevent this, the Allen lab is leveraging nanoparticles (i.e., liposomes) to encapsulate PARPi and ATRi. Through this process, the Allen lab has shown a reduction in the level of blood toxicity seen with this drug combination. The proposed research will further assess these liposomes in mice that have tumors transplanted from an OC patient.
The Allen lab has also shown that PARPi+ATRi is effective at killing several different OC cells. However, some OC cells do not respond to PARPi+ATRi. As a result, the research team will use artificial intelligence (AI) and gene testing of cancer cells to develop a model that can predict which patients will respond best to PARPi+ATRi.
The research team is well-equipped to move this research forward. Dr. Allen has over 20 years of expertise in nanomedicine and drug delivery. Dr. Lheureux, a medical oncologist and clinical investigator, has significant expertise in preclinical and clinical evaluation of cancer therapies. Jazz Pharmaceuticals (our partner organization), has successfully developed a nanomedicine-based cancer treatment, further enhancing the project's potential. If successful, this project will yield sufficient data to move this nanomedicine approach into the clinic and may ultimately improve outcomes for predefined HGSOC patients.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Allen, Christine J; Lheureux, Stephanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~